Intranasal TGF-β1 Reduces Stroke Damage in Mice
Author Information
Author(s): Ma Minmin, Ma Yuping, Yi Xueming, Guo Ruibing, Zhu Wusheng, Fan Xinying, Xu Gelin, Frey William H, Liu Xinfeng
Primary Institution: Department of Neurology, Jinling Hospital, Nanjing University School of Medicine
Hypothesis
Does intranasal administration of TGF-β1 enhance neurogenesis and reduce infarct volume after stroke in mice?
Conclusion
Intranasal administration of TGF-β1 reduces infarct volume, improves functional recovery, and enhances neurogenesis in mice after stroke.
Supporting Evidence
- TGF-β1 treated mice had significantly lower NSS scores at multiple time points after stroke.
- Infarct volume was significantly reduced in TGF-β1 treated mice compared to controls.
- TGF-β1 treatment resulted in a significant increase in BrdU-labeled cells in the SVZ and striatum.
Takeaway
Giving TGF-β1 through the nose helps mice recover better from a stroke by reducing brain damage and helping new brain cells grow.
Methodology
Mice underwent middle cerebral artery occlusion (MCAO) and were treated with intranasal TGF-β1; neurological function was assessed using modified NSS, and infarct volumes were measured.
Potential Biases
Potential bias in animal handling and assessment of neurological function.
Limitations
The study was conducted on mice, and results may not directly translate to humans.
Participant Demographics
Adult male C57BL/6 mice, weighing 25–30 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website